Cemiplimab (Libtayo) is available through the Cancer Drugs Fund. It is a possible treatment, in adults, for cutaneous squamous cell carcinoma that:
- has spread to deeper layers of skin, nearby lymph nodes or other parts of the body (locally advanced or metastatic) and
- can’t be treated using surgery or radiotherapy.
More evidence on cemiplimab is being collected, until July 2021. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.
Is this treatment right for me?
Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about making decisions about your care.
Questions to think about
- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?
Information and support
The NHS website may be a good place to find out more.
These organisations can give you advice and support:
- British Skin Foundation, 020 7391 6341
- Melanoma UK, 0808 171 2455
- Skcin – Karen Clifford Skin Cancer Charity, 0115 9819 116
- Cancer Research UK Patient Information, 0808 800 4040
- Macmillan Cancer Support, 0808 808 0000
You can also get support from your local Healthwatch.
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.
This page was last updated: 07 August 2019